Related Experiment Video
Updated: Aug 6, 2026

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
Published on: June 20, 2017
Aberrant GRP78 Phase Transition Sustains Endothelial IRE1α Signaling and Drives Blood-Brain Barrier Failure in
Honglin Zheng1, Qiang Li1, Haiyang Luo1,2,3,4
1Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Abstract:
Cerebral amyloid angiopathy (CAA) is a major cause of vascular cognitive impairment and lobar intracerebral hemorrhage, yet the mechanisms by which vascular amyloid-beta (Aβ) disrupts cerebrovascular integrity remain poorly defined. Here, we combined spatiotemporal single-cell and single-nucleus transcriptomics in APP23 mice with mechanistic studies in human brain endothelial cells and validation in human CAA-related hemorrhagic tissues to define the endothelial stress pathways driving disease progression. Endothelial cells emerged as an early and highly vulnerable vascular population during CAA development, characterized by persistent activation of endoplasmic reticulum (ER) stress programs with preferential engagement of the IRE1α branch. In vitro, Aβ40 preformed fibrils directly induced ER remodeling, aberrant solid-like phase transition of GRP78, sustained IRE1α-TRAF2-JNK signaling, endothelial apoptosis, and tight junction loss. In vivo, pharmacological inhibition of IRE1α with 4µ8C restored junctional integrity, reduced blood-brain barrier leakage, attenuated vascular amyloid pathology, and improved behavioral performance. Human CAA-related intracerebral hemorrhage specimens recapitulated endothelial ER stress, apoptotic activation, and tight junction depletion. These findings identify persistent endothelial IRE1α signaling as a key driver of cerebrovascular failure in CAA, highlighting its potential as a therapeutic target for vascular amyloidosis.
More Related Videos
Related Concept Videos
Cerebral Edema ll: Pathophysiology
Hepatic Encephalopathy
Alzheimer Disease ll: Pathophysiology
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

